Gut Microbiota and Risk of Coronary Heart Disease: a Two-sample Mendelian Randomization Study

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 9

PMID 38590695

Authors

Xiang-Zhi Hu

Ling-Ling Fu

Bin Ye

Man Ao

Ming Yan

Hong-Chao Feng

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between gut microbiota composition and coronary heart disease (CHD) has been recently reported in several observational studies. However, the causal effect of gut microbiota on coronary heart disease is uncharted.

Objective: This study attempted to investigate the effect of gut microbiota on coronary heart disease by Mendelian randomization (MR) analysis.

Methods: Through the two-sample MR method, single-nucleotide polymorphisms relevant to gut microbiota were selected as instrument variables to evaluate the causal association between gut microbiota and the risk of CHD.

Results: According to the selection criteria of the inverse variance-weighted average method, Class Actinobacteria, Class Lentisphaeria, Family Clostridiales vadinBB60group, Genus group, Genus , Genus , Genus , Genus , and Order Victivallales, presented a suggestive association with coronary heart disease.

Conclusion: This two-sample Mendelian randomization study found that gut microbiota was causally associated with coronary heart disease. Further randomized controlled trials are needed to clarify the protective effect of probiotics on coronary heart disease and their specific protective mechanisms.

References

Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A . Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021; 53(2):156-165. PMC: 8515199. DOI: 10.1038/s41588-020-00763-1. View

Pierce B, Burgess S . Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013; 178(7):1177-84. PMC: 3783091. DOI: 10.1093/aje/kwt084. View

Burgess S, Small D, Thompson S . A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2015; 26(5):2333-2355. PMC: 5642006. DOI: 10.1177/0962280215597579. View

Mazidi M, Shekoohi N, Covic A, Mikhailidis D, Banach M . Adverse Impact of spp. and Beneficial Role of spp. on Renal Function: Insights from a Mendelian Randomization Analysis. Nutrients. 2020; 12(8). PMC: 7468709. DOI: 10.3390/nu12082216. View

Fennema D, Phillips I, Shephard E . Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. Drug Metab Dispos. 2016; 44(11):1839-1850. PMC: 5074467. DOI: 10.1124/dmd.116.070615. View

Ren Z, Simons P, Wesselius A, Stehouwer C, Brouwers M . Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology. 2022; 77(1):230-238. PMC: 9970021. DOI: 10.1002/hep.32534. View

Liu H, Zhuang J, Tang P, Li J, Xiong X, Deng H . The Role of the Gut Microbiota in Coronary Heart Disease. Curr Atheroscler Rep. 2020; 22(12):77. DOI: 10.1007/s11883-020-00892-2. View

Lee Y, Kim Y, Seo J . Causal Association of Obesity and Dyslipidemia with Type 2 Diabetes: A Two-Sample Mendelian Randomization Study. Genes (Basel). 2022; 13(12). PMC: 9777695. DOI: 10.3390/genes13122407. View

Gavzy S, Kensiski A, Lee Z, Mongodin E, Ma B, Bromberg J . mechanisms of immune modulation and tolerance. Gut Microbes. 2023; 15(2):2291164. PMC: 10730214. DOI: 10.1080/19490976.2023.2291164. View

10.

Ni J, Li X, Zhang H, Xu Q, Wei X, Feng G . Mendelian randomization study of causal link from gut microbiota to colorectal cancer. BMC Cancer. 2022; 22(1):1371. PMC: 9804960. DOI: 10.1186/s12885-022-10483-w. View

11.

Zeng Y, Cao S, Yang H . Roles of gut microbiome in epilepsy risk: A Mendelian randomization study. Front Microbiol. 2023; 14:1115014. PMC: 10010438. DOI: 10.3389/fmicb.2023.1115014. View

12.

Fandriks L . Roles of the gut in the metabolic syndrome: an overview. J Intern Med. 2016; 281(4):319-336. DOI: 10.1111/joim.12584. View

13.

Mazidi M, Dehghan A, Banach M, The Lipid And Blood Pressure Meta-Analysis Collaboration Lbpmc Group And The International Lipid Expert Panel Ilep . Genetically Higher Level of Mannose Has No Impact on Cardiometabolic Risk Factors: Insight from Mendelian Randomization. Nutrients. 2021; 13(8). PMC: 8398879. DOI: 10.3390/nu13082563. View

14.

Di Angelantonio E, Thompson A, Wensley F, Danesh J . Coronary heart disease. IARC Sci Publ. 2012; (163):363-86. View

15.

Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A . Analysis of Gut Microbiota in Coronary Artery Disease Patients: a Possible Link between Gut Microbiota and Coronary Artery Disease. J Atheroscler Thromb. 2016; 23(8):908-21. PMC: 7399299. DOI: 10.5551/jat.32672. View

16.

Yoo J, Sniffen S, McGill Percy K, Pallaval V, Chidipi B . Gut Dysbiosis and Immune System in Atherosclerotic Cardiovascular Disease (ACVD). Microorganisms. 2022; 10(1). PMC: 8780459. DOI: 10.3390/microorganisms10010108. View

17.

Kintu C, Soremekun O, Kamiza A, Kalungi A, Mayanja R, Kalyesubula R . The causal effects of lipid traits on kidney function in Africans: bidirectional and multivariable Mendelian-randomization study. EBioMedicine. 2023; 90:104537. PMC: 10070509. DOI: 10.1016/j.ebiom.2023.104537. View

18.

Esteve E, Ricart W, Fernandez-Real J . Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?. Curr Opin Clin Nutr Metab Care. 2011; 14(5):483-90. DOI: 10.1097/MCO.0b013e328348c06d. View

19.

Hemani G, Zheng J, Elsworth B, Wade K, Haberland V, Baird D . The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7. PMC: 5976434. DOI: 10.7554/eLife.34408. View

20.

Xu H, Jin C, Guan Q . Causal Effects of Overall and Abdominal Obesity on Insulin Resistance and the Risk of Type 2 Diabetes Mellitus: A Two-Sample Mendelian Randomization Study. Front Genet. 2020; 11:603. PMC: 7343715. DOI: 10.3389/fgene.2020.00603. View